The board of directors of CARsgen Therapeutics Holdings Limited announces that Dr. Huabing LI ("Dr. Li") tendered his resignation as an independent non-executive Director with effect from April 29, 2024 due to his other business commitments which require more of his attention and dedication. Following the resignation of Dr. Li, he also ceased to act as the chairman of the remuneration committee (the "Remuneration Committee") and a member of each of the audit committee (the "Audit Committee") and the nomination and corporate governance committee (the "Nomination and Corporate Governance Committee") of the Company. The Board announced that Dr. Wen ZHOU ("Dr. Zhou") has been appointed as an independent non-executive Director, the chairman of the Remuneration Committee, a member of the Nomination and Corporate Governance Committee and a member of the Audit Committee with effect from April 29, 2024.

Dr. Zhou, aged 49, is currently working as a professor at the School of Basic Medical Sciences, Central South University. Dr. Zhou received her Ph.D. degree in Medicine in December 2009 from Central South University. She served as postdoctoral researcher in the University of Utah and School of Medicine in the University of Iowa.

She has published multiple articles as corresponding author in leading international academic journals such as Cell Metabolism, Nature Communications, Advanced Science, Microbiome, Leukemia and Cell Reports. Dr. Zhou is a youth member of the Chinese Society for Cell Biology and a member of the Oncology Committee of the Chinese Society of Cell Biology, as well as an editor and reviewer for several journals (Frontiers oncology, Cancers, etc.).